KING SIGNED

Project "KING" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

The need of high quality and cost-efficient hemodynamic and metabolic state monitoring devices is increasing exponentially, due to e.g. ageing population, chronic health conditions, health support system advance in developing courtiers and rural areas and the growing number of cases of chronic conditions in Europe and worldwide. Existing monitoring technologies are either very basic (e.g. ECG and heart rate), energy consuming or are difficult in use and installation among many other drawbacks. Several research studies suggest using alternative urinary ammonium measurements (e.g. 24-hours analysis). But urine anion and osmolar gaps connected to this type of analysis are not accurate enough to be reliable surrogate measures, since this method requires sample treatment. KARDIA a company founded in 1995 in Milan, developed a monitoring device that doesn’t require sample treatment, is non-invasive, low cost, low energy consuming and it is easy to use, install, move, handle: K.IN.G.- Kidney INstantaneous monitorinG. K.IN.G. aims to reduce morbidity and mortality rates among patients and to optimize therapeutic strategies by providing a cost-effective innovative and non-invasive monitoring solution. The solution also simplifies work of medical staff as it is portable and easy to use. K.IN.G. offers strong environmental advantages, as it diminish the energy consumption by 50%. It. also has the potential to boost the growth of KARDIA, reaching unprecedented sales parameters leading to the creation of new jobs and to contribute to KARIDA’s mission to ensure gender balance by recruiting female staff.